Many imidazoquinolines are synthetic TLR activators, including resiquimod (R848), a potent dual TLR7/8 agonist that has recently gained attention as a cancer immunotherapy agent due to its ability to reprogram TAMs in subcutaneous tumor models5–7. This evidence concerns the gene TLR7 and neoplasm.